Vitrolife (Q3 initial take): Technologies drives Q3 sales beat - Redeye

Vitrolife’s Q3 sales beat expectations by 4%, driven by Technologies. Organic growth of 21% in Technologies lifted group sales to SEK884m. The gross margin was supported by a one-off US tariff refund of cSEK9m. Adjusted for the refund, EBITDA of SEK270m was 2% below expectations, as cost inflation weighed on the gross margin.

Länk till analysen i sin helhet: https://www.redeye.se/research/1188217/vitrolife-q3-initial-take-technologies-drives-q3-sales-beat?utm_source=finwire&utm_medium=RSS